Please check your internet connection and try again.
# Flupentixol and Melitracen
## Overview
Flupentixol is a typical (first-generation) antipsychotic of the thioxanthene class. Melitracen is a tricyclic antidepressant (TCA). This combination product is used for the treatment of anxiety and depression, particularly when accompanied by a lack of motivation, apathy, and withdrawal.
## Primary Indications
* Anxiety disorders
* Depressive disorders
* Mixed anxiety and depressive states
* Situational depression, apathy, and withdrawal
## Adult Dosing
The typical starting dose is one tablet (0.5 mg flupentixol/10 mg melitracen) once daily. This can be increased to two tablets daily, taken as one tablet twice daily.
**Maximum dose:** Two tablets (1 mg flupentixol/20 mg melitracen) per day.
Dosing adjustments should be individualized based on patient response and tolerability.
## Pediatric Dosing
There is **no established pediatric dosing** for flupentixol and melitracen. Its use in children and adolescents is generally not recommended due to lack of efficacy and safety data.
## Dose Adjustments
* **Hepatic Impairment:** Caution is advised. Dose reduction may be necessary. Specific guidelines are not well-established.
* **Renal Impairment:** Caution is advised. Dose reduction may be necessary. Specific guidelines are not well-established.
* **Elderly:** May be more sensitive to adverse effects. Lower starting doses and slower titration may be warranted.
## Contraindications
* Hypersensitivity to flupentixol, melitracen, or any excipient.
* Circulatory collapse.
* CNS depression, including alcohol or barbiturate intoxication.
* Comatose states.
* Bone marrow depression.
* Untreated narrow-angle glaucoma.
* Prostatic hypertrophy with urinary retention.
* Pheochromocytoma.
* Concurrent use with MAO inhibitors or within 14 days of discontinuing MAO inhibitors (risk of serotonin syndrome or hypertensive crisis).
* Acute myocardial infarction or other recent cardiac events.
## Adverse Effects
**Common:** Drowsiness, dry mouth, blurred vision, constipation, dizziness, headache, insomnia, restlessness, fatigue, increased appetite, weight gain.
**Less Common/Serious:**
* **Antipsychotic-related:** Extrapyramidal symptoms (EPS) including akathisia, dystonia, parkinsonism, tardive dyskinesia (risk increases with duration of use). Neuroleptic Malignant Syndrome (NMS) – a rare but potentially fatal condition characterized by fever, muscle rigidity, altered mental status, and autonomic instability. Hyperprolactinemia.
* **TCA-related:** Orthostatic hypotension, arrhythmias (especially with overdose), anticholinergic effects (urinary retention, constipation, blurred vision, dry mouth), sedation, confusion, seizures (especially with overdose or in susceptible individuals), blood dyscrasias.
* **Other:** Sexual dysfunction, ECG changes, increased risk of falls, potential for QTc prolongation.
## Key Drug Interactions
* **MAO Inhibitors:** Contraindicated due to risk of serotonin syndrome or hypertensive crisis.
* **Other CNS Depressants (alcohol, benzodiazepines, opioids):** Additive sedative effects.
* **Anticholinergic Agents:** Increased anticholinergic effects.
* **Antihypertensives:** Reduced antihypertensive effect (especially adrenergic blockers).
* **QTc Prolonging Agents:** Increased risk of torsades de pointes.
* **CYP Enzyme Inhibitors/Inducers:** May affect flupentixol and melitracen metabolism.
## Monitoring
* **Mental status and psychiatric symptoms:** Assess efficacy and presence of adverse effects like EPS or worsening depression/suicidality.
* **Vital signs:** Blood pressure (including orthostatic), heart rate.
* **Neurological assessment:** Monitor for EPS.
* **Weight and metabolic parameters:** Particularly with long-term use.
* **ECG:** Consider in patients with pre-existing cardiac conditions, risk factors for QTc prolongation, or symptoms suggestive of cardiac events.
* **Blood cell counts:** If fever or signs of infection occur.
## Clinical Pearls
* This combination is not available in all regions.
* Due to the potential for sedation, patients should be advised to avoid operating heavy machinery or driving until they know how the medication affects them.
* The potential for suicidal thoughts and behaviors exists with antidepressant use, especially during initial treatment or dose changes. Close monitoring is essential.
* Discontinuation should be gradual to avoid withdrawal symptoms.
***
**Disclaimer:** This information is intended for clinical use and does not replace comprehensive drug information resources. Always consult the most current prescribing information and relevant guidelines for definitive patient management.
